Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2017 · 10-Q
Revenue$2.80M$2.80M−31.0% vs Q2 2016 Net Income-$1.95M-$1.95MN/M vs Q2 2016 EPS Diluted-$0.46-$0.46N/M vs Q2 2016 Gross Profit$1,036,000−50.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,624,000N/M Free Cash Flowderived-$1,674,000N/M Margins · derivedGross margin37.0%−14.5 pt vs Q2 2016
Operating margin-106.7%−60.9 pt vs Q2 2016
Net margin-69.7%−26.2 pt vs Q2 2016
ended Sep 30, 2016 · filed Nov 15, 2016 · 46 d after period end